Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVES: Linaclotide is a guanylate cyclase-C agonist approved in the United States, Canada, and Mexico at a once-daily 145-μg dose for the treatment of chronic idiopathic constipation (CIC); a once-daily 72-μg dose for CIC recently received FDA approval. The trial objective was to evaluate the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenfeld, Philip, Lacy, Brian E, Chey, William D, Lembo, Anthony J, Kurtz, Caroline B, Reasner, David S, Bochenek, Wieslaw, Tripp, Kenneth, Currie, Mark G, Fox, Susan M, Blakesley, Rick E, O’Dea, Christopher R, Omniewski, Nicholas D, Hall, Michael L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Functional GI Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770595/
https://www.ncbi.nlm.nih.gov/pubmed/29091082
http://dx.doi.org/10.1038/ajg.2017.230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770595/
https://www.ncbi.nlm.nih.gov/pubmed/29091082
http://dx.doi.org/10.1038/ajg.2017.230

Ejemplares similares